LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the publication* in the April 18, 2007 issue of the Journal of Neuroscience a study by researchers at the University of Colorado and National Jewish Medical and Research Center demonstrating that the Company’s first orally available catalytic antioxidant, AEOL 11207, demonstrated neuroprotection in an animal model of Parkinson’s disease (“PD”). The study also showed that the compound has favorable blood-brain barrier permeability.
